← Leaderboards
Vimla Band
Tufts Medical Center
$8,204,383
Attributed
$8,204,383
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $608.8K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,204,383 · 7
By mechanism
R01$7,671,891 · 5
R21$379,200 · 1
R03$153,292 · 1
Top collaborators
No co-investigators on record.
Most similar at Tufts Medical Center
Same institution · by research overlap
- Nickolai Anatoly Barlev$1,304,117
Others in their field
Top investigators on “Genetic Transcription”
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$69,905,031
- Bing Ren · Ludwig Institute For Cancer Research$61,600,123
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$54,253,356
- Richard Gibbs · Baylor College Of Medicine$53,550,246
- John A Tainer · Scripps Research Institute$51,251,962
- Deepak Srivastava · J. David Gladstone Institutes$50,027,907
Research focus
Genetic TranscriptionPathway InteractionsTumorigenesisBaseOncogenicCellsProteinsMalignant NeoplasmsApoptosisTranscription FactorCell ProliferationComplexMutationProtein Structure FunctionOncogenesTumor Suppressor GenesIn VitroGene TargetingCancer BiologyGene ExpressionPreventLeadOverexpressionHomologous Gene
Grant awards (35)
Co-Oncogenic Role of ECD in HER2-Driven Breast Cancer$76,750
R03 · FY2022 · CA · contact PI
Co-Oncogenic Role of ECD in HER2-Driven Breast Cancer$76,542
R03 · FY2021 · CA · contact PI
Ecdysoneless, A Novel Regulator of Androgen Receptor$172,293
R21 · FY2020 · CA · contact PI
Ecdysoneless, A Novel Regulator of Androgen Receptor$206,907
R21 · FY2019 · CA · contact PI
Ecd as a regulator of cell cycle and breast oncogenesis$308,138
R01 · FY2015 · CA · contact PI
Ecd as a regulator of cell cycle and breast oncogenesis$49,363
R01 · FY2015 · CA · contact PI
Ecd as a regulator of cell cycle and breast oncogenesis$298,894
R01 · FY2014 · CA · contact PI
Ecd as a regulator of cell cycle and breast oncogenesis$49,363
R01 · FY2014 · CA · contact PI
Ecd as a regulator of cell cycle and breast oncogenesis$289,650
R01 · FY2013 · CA · contact PI
Ecd as a regulator of cell cycle and breast oncogenesis$308,138
R01 · FY2012 · CA · contact PI
Ecd as a regulator of cell cycle and breast oncogenesis$308,138
R01 · FY2011 · CA · contact PI
A novel regulator of p53$252,802
R01 · FY2011 · CA · contact PI
A novel regulator of p53$260,621
R01 · FY2010 · CA · contact PI
A novel regulator of p53$260,621
R01 · FY2009 · CA · contact PI
A novel regulator of p53$253,086
R01 · FY2008 · CA · contact PI
A novel regulator of p53$201,390
R01 · FY2007 · CA · contact PI
A novel regulator of p53$68,982
R01 · FY2007 · CA · contact PI
A novel regulator of p53 function$264,202
R01 · FY2006 · CA · contact PI
ADA3: a novel target for HPV16 E6 oncoprotein$233,232
R01 · FY2006 · CA · contact PI
ADA3: a novel target for HPV16 E6 oncoprotein$97,020
R01 · FY2006 · CA · contact PI
ADA3: a novel target for HPV16 E6 oncoprotein$338,200
R01 · FY2005 · CA
A novel regulator of p53 function$270,560
R01 · FY2005 · CA
ADA3: a novel target for HPV16 E6 oncoprotein$338,200
R01 · FY2004 · CA
A novel regulator of p53 function$270,560
R01 · FY2004 · CA
ADA3: a novel target for HPV16 E6 oncoprotein$338,200
R01 · FY2003 · CA
A novel regulator of p53 function$270,560
R01 · FY2003 · CA
THE ROLE OF A NOVEL GAP IN EPITHELIAL ONCOGENESIS$250,765
R01 · FY2003 · CA
ADA3: a novel target for HPV16 E6 oncoprotein$359,894
R01 · FY2002 · CA
A novel regulator of p53 function$288,063
R01 · FY2002 · CA
THE ROLE OF A NOVEL GAP IN EPITHELIAL ONCOGENESIS$253,067
R01 · FY2002 · CA
HUMAN MAMMARY EPITHELIAL CELL IMMORTALIZATION$241,342
R01 · FY2002 · CA
THE ROLE OF A NOVEL GAP IN EPITHELIAL ONCOGENESIS$245,699
R01 · FY2001 · CA
HUMAN MAMMARY EPITHELIAL CELL IMMORTALIZATION$235,254
R01 · FY2001 · CA
THE ROLE OF A NOVEL GAP IN EPITHELIAL ONCOGENESIS$238,544
R01 · FY2000 · CA
HUMAN MAMMARY EPITHELIAL CELL IMMORTALIZATION$229,343
R01 · FY2000 · CA